Direct feedback and specialist expertise from our community (you!) helps keep Drug Hunter content relevant and high quality. Featured Drug Hunter reviewers who share helpful expert insights, feedback, and commentary are highlighted below, in no particular order. We always appreciate new feedback and thoughts from our readership. If you’d like to participate in reviewing content please let us know here.
Any views expressed on Drug Hunter are not necessarily those of the commentators or reviewers, and any ideas, commentary, or content expressed on Drug Hunter are not those of any commentators or reviewers’ current or past employers.
Joachim Rudolph – Oncology Drug Discovery and New Modalities
Joachim Rudolph is a Senior Principal Scientist in the Discovery Chemistry Department at Genentech, with a joint appointment in Genentech’s Discovery Oncology Department. An organic chemist by training, Joachim started his career in the Central Research Department at Bayer in Germany and later transferred to the Pharmaceutical Research Center at Bayer Corporation in West Haven, Connecticut. Joachim joined Genentech in 2007 and has been a chemistry team leader and project leader for multiple small-molecule discovery programs, with a focus in the area of oncology and a growing involvement in early discovery programs and new modalities. Joachim is an Editorial Advisory Board member of the Journal of Medicinal Chemistry and has been an active member of the AACR, as a speaker, session chair, and Chemistry in Cancer Research (CICR) Steering Committee member. In 2021, Joachim assumed the role of the CICR Steering Committee Chair. Read more about Joachim here.
Kim Huard – Metabolic Diseases and Novel Targets Drug Discovery
Kim Huard joined Genentech in 2018 where she currently leads drug discovery programs. An organic chemist by training, Kim started her career at Pfizer in 2010 as a medicinal chemist in the cardiovascular and metabolic disease research unit. She led chemistry teams on various drug discovery programs which resulted in the discovery of three clinical candidates. Her interests include exploratory programs, hit finding activities and tissue-specific delivery. She is a member of the Scientific Advisory Board of the Chemical Probes Portal (chemicalprobes.org).
Christian Gampe – Immunology Drug Discovery
Christian Gampe received his Diploma in chemistry from the University of Würzburg (Germany) in 2006 and his Dr. Sc. from ETH Zürich under supervision of Prof. Carreira in 2011. After postdoctoral studies at Harvard with Prof. Kahne, Christian joined the Global Discovery Chemistry group at the Novartis Institutes for Biomedical Research in Cambridge, MA, in 2013, where he worked on small molecule drug discovery programs and new modalities alike, publishing on synthetic mRNA modification (here and here), synthetic methods, and medicinal chemistry isosteres. During his time in Boston, Christian was an active member of the Beacon VP biotech investment fund. In 2020, he moved to the west coast and joined the Discovery Chemistry group at Genentech in pursuit of drugs for the undruggable and finding new treatments for autoimmune diseases.
Dian Su – Drug Metabolism and Pharmacokinetics (DMPK)
Dian Su is a Senior Director, DMPK, at Mersana Therapeutics. Her research focuses on antibody-drug conjugates (ADCs). Previously, Dian was a Principal Scientist in the DMPK department at Genentech. Her research was primarily focused on ADC/small molecule/peptide DMPK areas mainly in the pre-clinical stage. Before joining Genentech in 2012, Dian held a postdoctoral position at the NIH Proteomics Research Resource for Integrative Biology in Pacific Northwest National Laboratory. She earned her Ph. D. in Chemistry from Washington University in St. Louis and studied DNA photoproducts and protein-ligand interactions.
Julien Lefranc – Oncology Drug Discovery and Degraders
Julien Lefranc is a Principal Scientist at Merck KGaA in Darmstadt and is a member of the Early Career Advisory Board at ChemMedChem. Julien Lefranc studied chemistry in Marseille and Montpellier. After his master’s degree, Julien moved to the University of Manchester to carry out his PhD with Prof. Jonathan Clayden working on organolithium reactions and in 2012, he moved to Germany for a post-doctoral stay with Prof. Dirk Trauner working natural products synthesis. In 2014, Julien started his industrial career with Bayer in Berlin where he worked on several oncology projects. In 2020, he was promoted to Senior Scientist in Medicinal Chemistry at the Innovation Campus Berlin. He assumed his current position in 2021.
Michael Koehler – Infectious Disease Drug Discovery
Michael Koehler received his Ph.D. from Stanford University in 2000, and has been a medicinal chemist at Genentech since that time, working in a variety of therapeutic areas. He was recognized as an ACS Hero of Chemistry in 2017 as part of the team that discovered vismodegib (Erivedge), and more recently has been working on antibiotic drug discovery, principally on enabling the arylomycins as novel, broad spectrum antimicrobials.
Christian Kuttruff – Respiratory Disease Drug Discovery & Business Development
Christian Kuttruff is currently an Associate Director of Global Business Development & Licensing in Inflammation and NCE Technologies at Boehringer Ingelheim. Christian studied chemistry at the Technical University in Munich and obtained his PhD in 2012 under the guidance of Prof. Dirk Trauner at the University of Munich, where he focused on the synthesis of natural products. After postdoctoral studies at the Scripps Research Institute in La Jolla with Prof. Phil Baran, he joined Boehringer Ingelheim as a medicinal chemist in 2014. He worked as a project leader in the areas of respiratory diseases, immune-oncology and immunology before assuming his current role.
Callie Bryan – Immunology & Kinase Drug Discovery
Callie Bryan is a Senior Principal Scientist at Janssen R&D at Spring House PA. Upon completing her PhD at The Scripps Research Institute with Chi-Huey Wong and post-doctoral studies with Linda Hsieh-Wilson at CalTech, joined Amgen in Medicinal Chemistry where I worked in both the Neuro and Oncology space. Callie joined Genentech in 2012, focusing mainly on Oncology and Immunology and then moved to Janssen R&D at Spring House PA in January of 2020.
Ron Li – General Medicine
Ron Li is an internal medicine physician and Clinical Assistant Professor of Medicine (Hospital Medicine and Biomedical Informatics) at Stanford University School of Medicine. He is an attending physician on the university teaching service, where he cares for hospitalized patients and trains medical students and residents at Stanford Hospital. He is also the Medical Informatics Director for Digital Health and AI Clinical Integration at Stanford Health Care, where his work is centered around the design, implementation, and evaluation of novel digitally enabled systems of care delivery. He received his MD from Northwestern University and completed his residency in internal medicine and fellowship in clinical informatics at Stanford University School of Medicine. He is Board Certified in Internal Medicine and Clinical Informatics.
Jacob Schwarz – Neuroscience Drug Discovery
Jacob Schwarz has over 20 years of medicinal chemistry experience and has held positions of increasing importance in the Parke-Davis, Pfizer, and Genentech organizations. He is currently Head of Chemistry at ESCAPE Bio, a clinical stage company developing novel, precisely targeted therapies for genetic neurodegenerative diseases. Jake is currently Chair of the American Chemical Society’s Division of Medicinal Chemistry. He received a PhD from Colorado State University under the guidance of A. I. Meyers, followed by an NIH postdoctoral fellowship in the laboratories of Samuel Danishefsky at Memorial Sloan-Kettering Cancer Center.
Anthony Vaganos – Commercial
Anthony Vaganos is an experienced US and global commercial leader in oncology, rare disease, and neuroscience therapeutics across the lifecycle inducing business development, early-to-late stage design and decision making, pricing and market access strategy, and launch marketing. Anthony is currently an oncology global marketing director at GSK focused on pivotal trial investment decisions and launch planning. He previously worked at Genentech in commercial functions on multiple franchises including hematology oncology, HER2 breast cancer, neuroscience, and rare disease. Anthony holds an MBA from the Wharton School, a Masters in biotechnology from University of Pennsylvania, and a Bachelors from Cornell University.
Joanna Lee – In Vitro Pharmacology
Joanna Lee is a Senior Scientist in the Department of Biochemical and Cellular Pharmacology at Genentech. A cell biologist by training, Joanna received her Ph.D. in Biology from Stanford University studying centrosomes and cilia. She also conducted a postdoc in Stanford’s Mechanical Engineering Department, generating biomaterials to study how the mechanical properties of the tumor microenvironment induce cancer invasion. In addition to pharmacology and assay development, she specializes in 3D cell culture models of the tumor microenvironment.
Adi Murthy – Cell Biology and Cancer Immunology
Aditya Murthy is currently Director of Cell Biology at Interline Therapeutics. His motivation is to leverage the growing catalog of human genetic variation in inflammatory diseases in order to better understand their underlying mechanisms and develop novel therapeutics for chronic diseases. Adi obtained his Ph.D. at the University of Toronto in Medical Biophysics, followed by a post-doctoral fellowship at Genentech, Inc. There, he investigated the genetics and mechanisms of inflammatory bowel disease. As a group leader in Cancer Immunology at Genentech, Adi’s research focused on translating insights from human genetics of chronic inflammatory diseases to actionable pathways for immuno-oncology (Freund et al. 2020; Lim et al. 2019; Lim et al. 2020; Maculins et al. 2021; Samie, et al 2018).
Yoana Dimitrova – Challenging Targets and Drug Discovery Strategy
Yoana Dimitrova is a Senior Scientist in the Structural Biology Department at Genentech. A protein biochemist and structural biologist by training, Yoana has a passion for studying the intricate mechanistic assembly and regulation of macromolecular complexes. After receiving her PhD in Biochemistry from Vanderbilt Medical School with Prof. Walter Chazin, she continued her postdoctoral work with Prof. Stephen Harrison at Harvard Medical School. Yoana joined Genentech in 2017 and has been a structural biology lead on a number of unprecedented drug targets, focused on the strategy of enabling early discovery programs.
Naomi Rajapaska – Respiratory Disease Drug Discovery
Naomi is a medicinal chemist at Interline with over seven years of experience in structure- and property-based drug design. She started her industrial career at the Novartis Institutes for Biomedical Research in the area of antiviral drug discovery. Prior to Interline, she was a Senior Scientist and team leader at Genentech, where she contributed to the medicinal chemistry efforts on projects in immunology and oncology. Naomi received a Ph.D. in organic chemistry from Harvard University under the guidance of Eric Jacobsen, studying asymmetric catalysis and synthesis, and a B.S. in chemistry from Stanford University.
Dennis C. Koester – Infectious and Tropical Disease Drug Discovery
Dennis is a drug hunter at the Novartis Institutes for Biomedical Research (NIBR) in Emeryville, CA. His experience as a Medicinal Chemist spans across property-driven as well as target-based drug discovery programs in infectious and tropical diseases. Recently, Dennis helped advance programs on Chagas disease and Malaria as a project team leader. He is driven by contributing to disease areas with extremely high unmet medical need. Dennis obtained his PhD in Organic Chemistry from the University of Göttingen in 2013 specializing in carbohydrate chemistry and transition-metal catalysis. He worked at the University of Kyoto in 2011 and at the University of Münster in 2013. Before starting his career in Global Drug Discovery at Novartis in 2015, he conducted postdoctoral research at Stanford. Dennis had outstanding mentors throughout his career and was fortunate to be a Kekule fellow, a fellow of the Alexander von Humboldt foundation, the Japanese Society for the Promotion of Science (JSPS), and the Studienstiftung des deutschen Volkes.
Bryan McKibben – Medicinal Chemistry
Bryan McKibben has over 20 years of experience as a medicinal chemist. Bryan started his career in biotech with Cadus Pharmaceuticals which was subsequently bought by OSI Pharmaceuticals. He later joined Boehringer-Ingelheim Pharmaceuticals and worked in immunology / inflammatory drug discovery. Currently, Bryan is Project Director (Principal Scientist II) in Drug Discovery at AbbVie where he leads a team of interdisciplinary scientists. Over his career, Bryan played a key role in advancing multiple compounds into clinical trials. Bryan was trained as a synthetic organic chemist. He received a PhD with Professor Tomas Hudlicky at Virginia Tech, followed by a postdoctoral fellowship with Professor Victor Snieckus at the University of Waterloo.
- The 27 Lead Drug Molecules Acquired from Biotechs in 2021
- Billion-Dollar Molecules: Avacopan (Tavneos), a First-in-Class C5aR Antagonist Acquired by Amgen
- July 2022 Molecules of the Month Runners-Up
- Small Molecule and Biotechnology-Based Therapeutics for Immunology: 2021 IPO Review Pt. VI
- Drug Hunter Letters #3 – September 2022
- First Disclosures from EFMC-ISMC Nice, 2022
- Drug Discovery Resources
- Drug Discovery Posters and Cheat Sheets
- Drug Discovery IPOs and Industry Reviews
- Lists of Approved Drugs
- Classics in Drug Discovery
- Drug Discovery Books
- Drug Discovery Conferences
- What is a Drug Hunter?
- Topliss Tree and Topliss Scheme Posters
- PK Reference Table / Cheat Sheet
- Pd-Couplings Table / Cheat Sheet
- Phase I Drug Metabolism
- Approved Covalent Drug Mechanisms
- Why LogD Matters / LogD Poster
- Types of Kinase Inhibitors
- Unusual Molecular Interactions from the PDB
- Bioactivation of Structural Alerts
- The Square Cube Law
- Don’t Work on Things That Don’t Work
- What is a Biologic Drug Anyway?
- Managing Liver Injury (DILI) Risk
- Where Do Hits Come From?
JOIN SUBSCRIBERS from
- Johnson & Johnson
- Eli Lilly
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Novo Nordisk
- Merck KGaA
- Celgene (BMS)
- Daiichi Sankyo
- Kyowa Kirin
- LEO Pharma
- RA Capital
- ARCH Venture Partners
- MPM Capital
- The Column Group
- 5AM Ventures
- Versant Ventures
- Goldman Sachs
- Piper Sandler
- …and hundreds of others